Munich Re look at improving Cancer outcomes

As part of Munich Re’s Life Science Report 2025, they have investigated the projected impact of advances in cancer treatment and research. These advances will change how cancers are defined, prevented, diagnosed and treated and are expected to significantly improve cancer mortality.

Cancer is the leading cause of death among policyholders for most insurers worldwide, as such it demands investigation. Much progress has been made in the past couple of decades to improve cancer mortality, through both reducing cancer risk factors (such as the dramatic downturn in tobacco use) and better diagnosis and treatment. Mortality improvement trends are expected to accelerate as our understanding of cancer genetics are combined with artificial intelligence (AI).

AI will be used to both improve cancer risk prevention and diagnostics. AI analysis of an individual’s personal information such as health data, family history, genetic and epigenetic profiles, microbiome, living environment and exposure history, sometimes called a statistical biopsy, will give a better understanding of risk for a wide range of cancers. This could potentially allow for a personalised approach to risks, behaviours, and identification of which strategies may be most effective in addressing these factors.

Being able to diagnose cancer more accurately, and at earlier stages, should improve cancer mortality. AI has already led to refinements in imaging studies, and in blood, urine and tissue samples. AI can also be used to analyse the tumour’s genetic pattern, other associated biomarkers and an individual’s risk profile to allow for better prognosis and management approach. AI’s ability to recognise patters not apparent to humans will help with diagnostic tools such as imaging studies, pathologic specimen interpretation and photograph analysis.

More effective screening approaches will lead to earlier cancer diagnosis and improved cancer mortality. An important technology, ‘liquid biopsy’, is currently used to analyse fluids to look for markers indicating the presence of a cancer, typically used to detect residual cancer after treatment or recurrence. If a liquid biopsy test that can screen for multiple cancers in asymptomatic individuals could be brought to market at a price point where it is accessible to the masses, it would be a game changer. Though it would also raise concerns about over-diagnosis and surveillance bias, as some identified cancers may never post a significant mortality risk.

The combination of AI and genomic analysis of tumour cells and immune cells has led to the development of targeted treatments that exploit specific genetic patterns. These treatments are more precise and safer than chemotherapy, with the four key categories of therapies emerging being targeted monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines and adoptive cell immunotherapy.

With potential changes in how cancers are classified, product definitions will need to be modified. Instead of being classified based on their tissue of origin, it’s expected new cancer tests will be able to categorise cancers based on their underlying genetic causes – potentially leading to thousands of cancer subtypes.

Where previously terminal cancers become able to be managed and instead turn into chronic disease, there may be implications for living benefits products. Reduced mortality should be favourable for life insurances businesses, though the costs of more sophisticated, individualised cancer treatments may have a negative cost impact on health insurance businesses. Munich Re predict that advances in diagnosis and changes in diagnostic criteria are going to increase cancer incidence rates in the short term, but may decrease critical illness rates if major advances in cancer prevention are realised.

AI will also have implications for underwriting. AI-based diagnosis is likely to be more accurate and predictive than current methods, with fewer false positive and false negative results, enabling risk to be better assessed. Better monitoring post-cancer treatment will mean recurrence risk can be more accurately assessed too.

More news:

Southern Cross Health Trust to fund salaries of nursing positions at City Missions

This week is Privacy Week

Kiwi advisers believe AI could help improve advice delivery

Pharmac to fund or widen access to three treatments, including for skin cancer, from 1 June 2025

Nominations for the FSC industry awards open

The Financial Services Council (FSC) has opened entries for their 2025 Awards programme. The awards will be presented at the FSC Awards Dinner on 11 September 2025, at the Cordis Hotel in Auckland, as part of the FSC25 Conference. Entries are open to individuals, teams and organisations, with nominations closing 29 June 2025.

There are two new award categories this year.

• New: Innovation of the Year

• New: Excellence in ESG

• Emerging Trailblazer: sponsored by Swiss Re

• Excellence in Wellbeing and Inclusion: sponsored by Swiss Re

• Contribution to Community

• Team of the Year

• Workplace Savings

• Chair's Award for Service to the Industry

More news:

mySolutions webinar 'Getting more of the 'right kind' of referrals' is on 14 May

Investment News NZ produce  ‘Welcome to FAP-land’ report

Jon-Paul Hale talks about how service commissions could be structured

Gen Z expect the same digital experience with life insurers as they have with banks

Legal and regulatory update for the life and health insurance sector

29 Apr 2025 - The FMA release Jess Learns to Invest Episode 4 | Market Volatility and Your Investments with Brad Olsen. https://www.fma.govt.nz/library/podcast/jess-learns-to-invest-episode-4/

29 Apr 2025 - The FMA has announced the six fintech firms who will be testing their innovative products, services or business models in the FMA’s pilot regulatory sandbox.

The successful fintech firms are:

• ECDD Holdings Limited   - part of the exchange service Easy Crypto) intends to launch a yield bearing NZD-backed stablecoin and to generate revenue from interest earned on money held on trust in interest-bearing accounts.

• Emerge Group Limited   - intending on offering a digital-first business banking alternative for small and medium-sized enterprises (SMEs).

• Homeshare  - which appears to be an investment company aiming to assist period with home sharing schemes.

• IndigiShare  - with aims to offer a koha-loan platform designed to break down barriers to entry for indigenous businesses and provide funding for Māori entrepreneurs, startups, and SMEs, especially those with a strong social impact

• Invest in Farming Co-op - with intention to offer individuals a way to invest in agricultural businesses directly from their smartphones.

• Tandym Limited - currently offers full-service solutions for recruitment and workforce development and management, connecting businesses with top talent, we are unsure what their interest in financial services.

https://www.fma.govt.nz/news/all-releases/media-releases/fintech-sandbox-participants/

29 Apr 2025 - The FMA has published the first edition of FMA Financial Advisers Update. https://createsend.com/t/r-B06F256588858C182540EF23F30FEDED

29 Apr 2025 - The FMA have published a Consumer Confidence Factsheet. The results of the Consumer Confidence Survey indicate that that Māori and women are less likely like to feel confident in NZ's financial markets, and less likely to feel confident our financial markets are effectively regulated. The results indicate that Māori and women are less likely like to have health or life Insurance, but Māori are more likely to have funeral Insurance. https://www.fma.govt.nz/library/research/consumer-confidence-factsheet-2025/

29 Apr 2025 - The FMA release ‘5 mins with the FMA’ podcast #13: Consumer Confidence Survey. https://www.fma.govt.nz/library/podcast/5-mins-with-the-fma-podcast-13/

30 Apr 2025 - The Office of the Privacy Commissioner is asking for feedback on Privacy Amendment Bill (IPP3A) draft guidance. Feedback can be submitted between 30 April - 25 June 2025. https://www.privacy.org.nz/news/haveyoursay/

1 May 2025 - The RBNZ has released research which investigates why the ‘natural interest rate’ has fallen in New Zealand over recent decades. https://www.rbnz.govt.nz/hub/news/2025/05/research-investigates-why-the-natural-interest-rate-has-fallen-in-new-zealand-over-recent-decades